.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the general public market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the sign "BIOA," depending on to papers filed along with the Stocks as well as Exchange Payment. The provider has not publicly discussed an expected financial volume for the offering.The clinical-stage company touts lead prospect azelaprag, an orally provided tiny particle slated to get into stage 2 screening in combination along with semaglutide-- sold through Novo Nordisk under brand name Wegovy for weight reduction-- in the 1st one-half of upcoming year. Semaglutide is additionally offered as Ozempic and Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually designed to incorporate properly along with GLP-1 medications, increasing fat burning while maintaining muscle mass. The investigational drug was actually discovered to become well-tolerated amongst 265 individuals across 8 period 1 trials, according to BioAge.Formerly, BioAge got the help of Lilly to operate a trial blending azelaprag along with the Big Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetic issues as Mounjaro and also Zepbound for weight-loss. The companions are presently administering a stage 2 trial of azelaprag and tirzepatide, along with topline results expected in the 3rd quarter of 2025.The biotech is also planning a blood insulin sensitivity proof-of-concept trial assessing azelaprag as a monotherapy in the very first half of upcoming year to assist prospective indication growth. In addition, the company prepares to inquire the FDA for consent in the second fifty percent of 2025 to release human screening for an NLRP3 inhibitor targeting metabolic diseases and neuroinflammation.BioAge's expected relocate to the public market follows a small uptick in organized biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the current IPO landscape is a "mixed picture," with high-quality firms still debuting on the public markets, just in lowered amounts, according to PitchBook.